PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.49%
R&D reduction while GNPX shows 45.86% growth. Joel Greenblatt would examine competitive risk.
-24.67%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-17.97%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.31%
Similar EBITDA growth to GNPX's 21.51%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Similar operating income growth to GNPX's 21.49%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
184.62%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
18.43%
Similar pre-tax income growth to GNPX's 21.43%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.43%
Similar net income growth to GNPX's 21.43%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
58.16%
EPS growth exceeding 1.5x GNPX's 37.89%. David Dodd would verify competitive advantages.
58.16%
Diluted EPS growth exceeding 1.5x GNPX's 37.89%. David Dodd would verify competitive advantages.
96.23%
Share count reduction below 50% of GNPX's 26.50%. Michael Burry would check for concerns.
96.23%
Diluted share reduction below 50% of GNPX's 26.49%. Michael Burry would check for concerns.